We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.44%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.27B
AUM Growth
-$685M
Cap. Flow
+$6.49M
Cap. Flow %
0.2%
Top 10 Hldgs %
61.39%
Holding
65
New
6
Increased
5
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$77M
2
JANX icon
Janux Therapeutics
JANX
+$69M
3
CRGX
CARGO Therapeutics
CRGX
+$27.9M
4
BCYC
Bicycle Therapeutics
BCYC
+$20.6M
5
ITOS
iTeos Therapeutics
ITOS
+$17.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65.8M
3
ALEC icon
Alector
ALEC
+$24.4M
4
NKTX icon
Nkarta
NKTX
+$21.6M
5
OVID icon
Ovid Therapeutics
OVID
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
26
DELISTED
Adaptimmune Therapeutics
ADAP
$26.7M 0.82%
27,404,070
– –
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.11B
$24.2M 0.74%
3,418,068
– –
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
$24.1M 0.74%
+1,470,000
New +$27.9M
CLDX icon
29
Celldex Therapeutics
CLDX
$2.77B
$24.1M 0.74%
650,000
– –
PCVX icon
30
Vaxcyte
PCVX
$8.12B
$22.7M 0.69%
300,000
– –
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.28B
$22.5M 0.69%
1,250,385
– –
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.38B
$21.9M 0.67%
1,346,475
-4,645,004
-78% -$75M
LENZ
33
LENZ Therapeutics
LENZ
$162M
$21.1M 0.65%
1,219,774
– –
MDGL icon
34
Madrigal Pharmaceuticals
MDGL
$12.8B
$21M 0.64%
75,000
– –
NMRA icon
35
Neumora Therapeutics
NMRA
$298M
$20.4M 0.62%
2,071,450
– –
BCYC
36
Bicycle Therapeutics
BCYC
$294M
$18.4M 0.56%
+910,000
New +$20.6M
AVIR icon
37
Atea Pharmaceuticals
AVIR
$390M
$18M 0.55%
5,441,896
-703,965
-11% -$2.62M
PHVS icon
38
Pharvaris
PHVS
$2.44B
$16.9M 0.52%
900,000
– –
DYN icon
39
Dyne Therapeutics
DYN
$3.92B
$15.1M 0.46%
427,039
– –
TECX
40
Tectonic Therapeutic
TECX
$615M
$14M 0.43%
+849,143
New +$13.6M
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$376M
$10.9M 0.33%
+508,393
New +$11.7M
KROS icon
42
Keros Therapeutics
KROS
$211M
$8.57M 0.26%
187,500
– –
KLRS
43
Kalaris Therapeutics
KLRS
$104M
$8.17M 0.25%
491,069
– –
REPL icon
44
Replimune Group
REPL
$859M
$7.65M 0.23%
+850,341
New +$5.93M
VERV
45
DELISTED
Verve Therapeutics
VERV
$6.1M 0.19%
1,250,000
– –
GBIO
46
DELISTED
Generation Bio
GBIO
$5.77M 0.18%
204,687
– –
PRME icon
47
Prime Medicine
PRME
$565M
$3.6M 0.11%
700,000
– –
ATRA icon
48
Atara Biotherapeutics
ATRA
$75.6M
$3.46M 0.11%
406,679
-3
-0% -$45
PRQR icon
49
ProQR Therapeutics
PRQR
$240M
$3.39M 0.1%
2,042,771
-841,586
-29% -$1.63M
HOOK
50
DELISTED
HOOKIPA Pharma
HOOK
$3.38M 0.1%
571,732
+112,230
+24% +$890K
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2024 Portfolio in Review

As of Q2 2024, EcoR1 Capital held 65 positions worth $3.27B, down 17% from $3.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q2 2024 filing shows 6 new, 5 increased, 5 reduced and 10 closed positions. Its largest new stake was Janux Therapeutics: 1,469,818 shares worth $61.6M. The largest sale was Acadia Pharmaceuticals, an estimated $75M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • EcoR1 Capital's largest Q2 2024 buy was Janux Therapeutics: 1,469,818 shares worth $61.6M.
  • EcoR1 Capital added most to Morphic Holding, Inc. Common Stock in Q2 2024, an estimated $77M increase.
  • EcoR1 Capital's biggest Q2 2024 reduction was Acadia Pharmaceuticals, cutting an estimated $75M.
  • EcoR1 Capital fully exited Alector in Q2 2024, selling an estimated $24.4M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.27B portfolio in Q2 2024.
  • EcoR1 Capital opened 6 new positions and closed 10 in Q2 2024.
  • EcoR1 Capital's portfolio value fell 17% quarter-over-quarter to $3.27B.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.